🔎 Trials Near Me

Utama › Kanser Paru-paru › Pennsylvania › Harrisburg

Kajian klinikal Kanser Paru-paru di Harrisburg, PA

9 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Harrisburg (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Mengambil pesertaFasa 3
  • Penn State Milton S Hershey Medical Center, Hershey · 12 mi jauh
Umur 70 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06096844

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Mengambil pesertaFasa 3
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT04267848

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Mengambil pesertaFasa 3
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Mengambil pesertaFasa 3
  • Penn State Milton S. Hershey Medical Center, Hershey · 12 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06881784

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Mengambil pesertaFasa 3
  • Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey · 12 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06312137

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • Penn State Milton S Hershey Medical Center, Hershey · 12 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05624996

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2026 · NCT05642572

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2/3
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06616584

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Mengambil pesertaFasa 2
  • Penn State Milton S. Hershey Medical Center, Hershey · 12 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Jun 2025 · NCT03175224

Kajian Kanser Paru-paru di bandar lain

Kajian lain di Harrisburg

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.